180710 – TG Tasly agreement PR
Category: 2018
Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
20180604 PR ASCO Pexa-vec neoadjuvant data EN
Transgene Announces Upcoming Investor Meetings
20180524 PR financial meetings Q2 18
Combined General Meeting of May 23, 2018
20180523 TG AGM 2018 EN
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Alan Anthoney, et al. ASCO 2018, June 2018 – Abstract available on the ASCO website Download the poster here Poster Presentation
Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
20180517 PR ASCO poster accepted EN
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
Stephane Leung-Theung-Long, et al. PLOS One, May 2018 – Download the article Publication
Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
20180502 MISE A DISPO AG – US
€35.6 Million in Cash and Cash Equivalents as of March 31, 2018
20180426-Resultats-Q1-2018-EN
Pseudocowpox: A next generation viral vector for cancer immunotherapy
Karolina Rittner, et al. AACR 2018, April 2018 – Abstract available on the AACR 2018 website Download the poster here Poster Presentation
